AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice
Recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 562
- Registration Number
- NCT05637112
- Locations
- 🇦🇪
Research Site, Abu Dhabi, United Arab Emirates
Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece
Completed
- Conditions
- Heart Failure
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 257
- Registration Number
- NCT05635331
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AZD5055 solution for infusionDrug: AZD5055 film-coated tabletDrug: AZD5055 oral suspensionDrug: Rabeprazole, Delayed-release tablet
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT05630677
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1174
- Registration Number
- NCT05629585
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT05629234
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Phase 3
Recruiting
- Conditions
- Viral Lung Infection and Acute Respiratory Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2870
- Registration Number
- NCT05624450
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 291
- Registration Number
- NCT05603845
- Locations
- 🇦🇪
Research Site, Dubai, United Arab Emirates
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Terminated
- Conditions
- Breast Cancer
- Interventions
- Other: None (Observational Study)
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 78
- Registration Number
- NCT05592483
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT05587998
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Phase 3
Active, not recruiting
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Other: Placebo
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 352
- Registration Number
- NCT05583227
- Locations
- 🇬🇧
Research Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath